ClinicalTrials.gg
Active, not recruitingNCT07023081Updated Oct 23, 2026

A Study to Understand the Safety of the 20vPnC Vaccine in Healthy Chinese Adults, Children, and Infant

A Phase 1 interventional study of 20vPnC and 13vPnC in Pneumococcal Disease, sponsored by Pfizer. Active, not recruiting at 2 sites in China. Open to participants aged 42 Days to 49 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Pfizer · Phase 1, Interventional, and Prevention

Updated Oct 23, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
42 Days to 49 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections — 2 open to participants now, 3 under way, 1 of them phase 3. Pneumococcal 20-Valent Conjugate Vaccine · Pneumococcal Infections.

Enrollment
19th of 19
200 · median 668
Started
2025
with 1 other
Phase 1
3 of 19
1 open now
Registered
17th of 19
by date
Lead sponsor
16 of 19
Pfizer

Among the 19 studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections, this one is the 19th largest by enrollment, is one of 2 that started in 2025, is one of 3 in phase 1, and was the 17th registered.

Pneumococcal Infections

299 studies on the registry are indexed under Pneumococcal Infections; 26 are open to participants now.

Browse Pneumococcal Infections studies →

Open to participants now

2 of the 19 studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About Pneumococcal 20-Valent Conjugate Vaccine

Pneumococcal 20-Valent Conjugate Vaccine: first FDA approval 2021 (Prevnar 20). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.

This study: 42 Days to 49 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections, or all of them as a file.
02

Study summary

The purpose of this study is to learn about the safety of the 20-valent pneumococcal conjugate vaccine (20vPnC) among adults, children, and infants, as well as the immunogenicity of 20vPnC among infants and children under 2 years of age in China. This vaccine will be given as per the age-specific dosing schedules among healthy adults, children and infants in China.

This study is seeking healthy participants of 6 groups:

  • Group 1: Adults ≥18 to \<50 years of age
  • Group 2: Children ≥2 to \<6 years of age
  • Group 3: Children ≥12 months to \<2 years of age
  • Group 4: Infants ≥7 to \<12 months of age
  • Group 5: Infants ≥42 to ≤98 days of age
  • Group 6: Infants ≥42 to ≤98 days of age

All participants in Group 1 to 5, in this study will receive 20vPnC as per the age-specific dosing schedules:

  • Group 1: participants will receive 1 dose of 20vPnC.
  • Group 2: participants will receive 1 dose of 20vPnC.
  • Group 3: participants will receive 2 doses of 20vPnC. Dose 2 will be given 56 to 70 days after Dose 1.
  • Group 4: participants will receive 3 doses of 20vPnC. Dose 2 will be given 28 to 56 days after Dose 1, and Dose 3 will be given at 365 to \<455 days of age and at least 56 days after Dose 2.
  • Group 5: participants will receive 4 doses of 20vPnC. Dose 2 will be given 42 to 63 days after Dose 1, and Dose 3 should be given 42 to 63 days after Dose 2, and Dose 4 should be given at 365 to \<455 days of age.

Participants in Group 6 will be randomized in a 1:1 ratio to received either 20vPnC or 13vPnC:

- Group 6: participants will receive 4 doses of 20vPnC or 13vPnC. Dose 2 will be given 42 to 63 days after Dose 1, and Dose 3 should be given 42 to 63 days after Dose 2, and Dose 4 should be given at 365 to \<455 days of age.

The study will look at the experiences of people receiving the study vaccine. The study will also look at the immune response of some people receiving the study vaccine. This will help decide if the study vaccine is safe.

The total duration of taking part in the study from each group is:

  • Participants in Group 1 and Group 2 will take part for about 6 months, with 6 visits.
  • Participants in Group 3 will take part for about 8 months, with 9 visits.
  • Participants in Group 4 will take part for about 12 months, with 8 visits.
  • Participants in Group 5 and 6 will take part for about 16 to 19 months, with 11 visits.
03

Conditions studied

  • Pneumococcal Disease
04

Who can participate

Ages eligible
42 Days to 49 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key inclusion criteria:

  • Male or female participants:

    • Adults ≥18 to \<50 years of age
    • Children ≥2 to \<6 years of age
    • Children ≥12 months to \<2 years of age
    • Infants ≥7 to \<12 months of age
    • Infants ≥42 to ≤98 days of age
  • Healthy participants determined by clinical assessment and clinical judgment, to be eligible for the study.

Key exclusion criteria:

  • History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention, or any diphtheria toxoid-containing vaccine.
  • History of microbiologically proven invasive disease caused by S pneumoniae.
  • Congenital, functional, or surgical asplenia.
  • Previous vaccination with any licensed or pneumococcal vaccine, or planned receipt during study participation.
  • Determined as not eligible by the investigator based on the participant's past and present health condition(s), medication(s) and treatment(s).

Please refer to the study contact for further eligibility details.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
200 participants (actual)

Study arms

  • Experimental
    Cohort 1

    Participants will receive 1 dose of 20vPnC Vaccine.

    Biological: 20vPnC

  • Experimental
    Cohort 2

    Participants will receive 1 dose of 20vPnC Vaccine.

    Biological: 20vPnC

  • Experimental
    Cohort 3

    Participants will receive 2 doses of 20vPnC Vaccine on Day 1 (Vaccination 1) and 56 to 70 days after Vaccination 1 (Vaccination 2).

    Biological: 20vPnC

  • Experimental
    Cohort 4

    Participants will receive 3 doses of 20vPnC Vaccine on Day 1 (Vaccination 1), 28 to 56 days after Vaccination 1 (Vaccination 2), and at 365 to \<455 days of age and at least 56 days after Vaccination 2 (Vaccination 3).

    Biological: 20vPnC

  • Experimental
    Cohort 5

    Participants will receive 4 doses of 20vPnC Vaccine on Day 1 (Vaccination 1), 42 to 63 days after Vaccination 1 (Vaccination 2), 42 to 63 days after Vaccination 2 (Vaccination 3), and at 365 to \<455 days of age (Vaccination 4).

    Biological: 20vPnC

  • Experimental
    Cohort 6 (20vPnC)

    Participants will receive 4 doses of 20vPnC Vaccine on Day 1 (Vaccination 1), 42 to 63 days after Vaccination 1 (Vaccination 2), 42 to 63 days after Vaccination 2 (Vaccination 3), and at 365 to \<455 days of age (Vaccination 4).

    Biological: 20vPnC

  • Active comparator
    Cohort 6 (13vPnC)

    Participants will receive 4 doses of 13vPnC Vaccine on Day 1 (Vaccination 1), 42 to 63 days after Vaccination 1 (Vaccination 2), 42 to 63 days after Vaccination 2 (Vaccination 3), and at 365 to \<455 days of age (Vaccination 4).

    Biological: 13vPnC

Interventions

  • Biological20vPnC

    20vPnC vaccine

  • Biological13vPnC

    13vPnC vaccine

06

What researchers measure

Primary outcomes

  1. Percentage of participants reporting prespecified local reactions within 7 days following each study intervention

    Prespecified local reactions following each study intervention

    Time frame: Within 7 days of each study intervention

  2. Percentage of participants reporting prespecified systemic events within 7 days following each study intervention

    Prespecified systemic events following each study intervention

    Time frame: Within 7 days of each study intervention

  3. Percentage of participants reporting adverse events (AEs) from the first study intervention through 1 month following the last study intervention administration

    AEs occurring through 1 month following the last study intervention administration for participants of adults ≥18 to \<50 years of age at the time of consent, and children and infants ≥7 months to \<6 years of age at the time of consent.

    Time frame: 1 month after the last vaccination

  4. Percentage of participants reporting AEs from the first study intervention through 1 month following the third study intervention.

    AEs occurring from the first study intervention through 1 month following the third study intervention in infants ≥42 to ≤98 days of age at the time of consent.

    Time frame: From the first study intervention to 1 month after the third study intervention

  5. Percentage of participants reporting AEs from the fourth study intervention to 1 month following the fourth study intervention.

    AEs occurring from the fourth study intervention to 1 month following the fourth study intervention in infants ≥42 to ≤98 days of age at the time of consent.

    Time frame: From the fourth study intervention to 1 month after the fourth study intervention

  6. Percentage of participants reporting serious adverse events (SAEs) throughout the study

    SAEs through 6 months following last study intervention

    Time frame: From the first study intervention to 6 months after the last study intervention

07

Study locations

2 sites
  • Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention
    Nanning, Guangxi 530021, China
  • Wuming District Center for Disease Control and Prevention
    Chengxiang, Nanning 530199, China
08

References and documents

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Jun 2027, 23 months after the start.

Of 27 phase 1 interventional studies under Pneumococcal Infections, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 16. This study's planned 23 months is above that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 23, 2026: primary completion May 2027 → Jun 2027 and completion May 2027 → Jun 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 8, 2025
First posted
Jun 15, 2025
StartActual
Jun 15, 2025
Primary completionEst.
Jun 10, 2027was May 2027
CompletionEst.
Jun 10, 2027was May 2027
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
May 14, 2027→Jun 10, 2027
Oct 23, 2026
Study completion
May 14, 2027→Jun 10, 2027
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    Primary completion May 14, 2027→Jun 10, 2027
    Study completion May 14, 2027→Jun 10, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07023081
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jun 15, 2025
Start date
Jun 15, 2025
Primary completion
Jun 10, 2027 (estimated)
Completion
Jun 10, 2027 (estimated)
Last update
Oct 23, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pneumococcal 20-Valent Conjugate Vaccine

Start the discussion